Fluvastatin ameliorates podocyte injury in proteinuric rats via modulation of excessive Rho signaling

Journal of the American Society of Nephrology

Volumn 17, Issue 3, 2006, Pages 754-764

  Shibata, Shigeru ^a   Nagase, Miki ^a   Fujita, Toshiro ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CREATININE; FASUDIL; FLUINDOSTATIN; GUANOSINE TRIPHOSPHATASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PUROMYCIN AMINONUCLEOSIDE; RHO KINASE INHIBITOR; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; STATINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL DAMAGE; CELL PROTECTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CYTOSKELETON; DRUG MECHANISM; ELECTRON MICROSCOPY; ENZYME ACTIVATION; ENZYME REGULATION; INTERSTITIAL NEPHRITIS; KIDNEY INJURY; MALE; NONHUMAN; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; QUALITATIVE ANALYSIS; RAT; RENAL PROTECTION; WESTERN BLOTTING;

EID: 33645455275     PISSN: 10466673     EISSN: None     Source Type: Journal    
DOI: 10.1681/ASN.2005050571     Document Type: Article

References (48)

1. Scandinavian Simvastatin Survival Study Group: Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Lancet 344: 1383-1389, 1994
2. Serruys PW, de Feyter P, Macaya C, Kokott N, Fuel J, Vrolix M, Branzi A, Bertolami MC, Jackson G, Strauss B, Meier B: Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention: A randomized controlled trial. JAMA 287: 3215-3222, 2002
3. Sever PS, Dahlof B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J: Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): A multicentre randomised controlled trial. Lancet 361: 1149-1158, 2003
4. Ni W, Egashira K, Kataoka C, Kitamoto S, Koyanagi M, Inoue S, Takeshita A: Antiinflammatory and antiarterio-sclerotic actions of HMG-CoA reductase inhibitors in a rat model of chronic inhibition of nitric oxide synthesis. Circ Res 89: 415-421, 2001
5. Dechend R, Fiebeler A, Park JK, Muller DN, Theuer J, Mervaala E, Bieringer M, Gulba D, Dietz R, Luft FC, Haller H: Amelioration of angiotensin II-induced cardiac injury by a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor. Circulation 104: 576-581, 2001
6. Goldstein JL, Brown MS: Regulation of the mevalonate pathway. Nature 343: 425-430, 1990
7. Laufs U, Liao JK: Post-transcriptional regulation of endothelial nitric oxide synthase mRNA stability by Rho GTPase. J Biol Chem 273: 24266-24271, 1998
8. Van Aelst L, D'Souza-Schorey C: Rho GT: Pases and signaling networks. Genes Dev 11: 2295-2322, 1997
9. Hall A: Rho GT: Pases and the actin cytoskeleton. Science 279: 509-514, 1998
10. Gueler F, Rong S, Park JK, Fiebeler A, Menne J, Elger M, Mueller DN, Hampich F, Dechend R, Kunter U, Luft FC, Haller H: Postischemic acute renal failure is reduced by short-term statin treatment in a rat model. J Am Soc Nephrol 13: 2288-2298, 2002
11. Li C, Yang CW, Park JH, Lim SW, Sun BK, Jung JY, Kim SB, Kim YS, Kim J, Bang BK: Pravastatin treatment attenuates interstitial inflammation and fibrosis in a rat model of chronic cyclosporine-induced nephropathy. Am J Physiol Renal Physiol 286: F46-F57, 2004
12. Ota T, Takamura T, Ando H, Nohara E, Yamashita H, Kobayashi K: Preventive effect of cerivastatin on diabetic nephropathy through suppression of glomerular macrophage recruitment in a rat model. Diabetologia 46: 843-851, 2003
13. Kawachi H, Koike H, Kurihara H, Yaoita E, Orikasa M, Shia MA, Sakai T, Yamamoto T, Salant DJ, Shimizu F: Cloning of rat nephrin: Expression in developing glomeruli and in proteinuric states. Kidney Int 57: 1949-1961, 2000
14. Kawachi H, Koike H, Kurihara H, Sakai T, Shimizu F: Cloning of rat homologue of podocin: Expression in proteinuric states and in developing glomeruli, J Am Soc Nephrol 14: 46-56, 2003
15. Eddy AA, Michael AF: Acute tubulointerstitial nephritis associated with aminonucleoside nephrosis, Kidney Int 33: 14-23, 1988
16. Tang WW, Qi M, Warren JS, Van GY: Chemokine expression in experimental tubulointerstitial nephritis. J Immunol 159: 870-876, 1997
17. Wang Y, Chen J, Chen L, Tay YC, Rangan GK, Harris DC: Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein. J Am Soc Nephrol 8: 1537-1545, 1997
18. Bianchi S, Bigazzi R, Caiazza A, Campese VM: A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease. Am J Kidney Dis 41: 565-570, 2003
19. Nakamura T, Ushiyama C, Hirokawa K, Osada S, Inoue T, Shimada N, Koide H: Effect of cerivastatin on proteinuria and urinary podocytes in patients with chronic glomerulonephritis. Nephrol Dial Transplant 17: 798-802, 2002
20. Kano K, Nishikura K, Yamada Y, Arisaka O: No effect of fluvastatin on the bone mineral density of children with minimal change glomerulonephritis and some focal mesangial cell proliferation, other than an ameliorating effect on their proteinuria. Clin Nephrol 63: 74-79, 2005
21. Mundel P, Reiser J, Zuniga Mejia Borja A, Pavenstadt H, Davidson GR, Kriz W, Zeller R: Rearrangements of the cytoskeleton and cell contacts induce process formation during differentiation of conditionally immortalized mouse podocyte cell lines. Exp Cell Res 236: 248-258, 1997
22. Katoh M, Kurosawa Y, Tanaka K, Watanabe A, Doi H, Narita H: Fluvastatin inhibits O2- and ICAM-1 levels in a rat model with aortic remodeling induced by pressure overload. Am J Physiol Heart Circ Physiol 281: H655-H660, 2001
23. Abe K, Shimokawa H, Morikawa K, Uwatoku T, Oi K, Matsumoto Y, Hattori T, Nakashima Y, Kaibuchi K, Sueishi K, Takeshit A: Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 94: 385-393, 2004
24. Nagase M, Kaname S, Nagase T, Wang G, Ando K, Sawamura T, Fujita T: Expression of LOX-1, an oxidized low-density lipoprotein receptor, in experimental hypertensive glomerulosclerosis. J Am Soc Nephrol 11:1826-1836, 2000
25. Hino M, Nagase M, Kaname S, Shibata S, Nagase T, Oba S, Funaki M, Kobayashi N, Kawachi H, Mundel P, Fujita T: Expression and regulation of adrenomedullin in renal glomerular podocytes. Biochem Biophys Res Commun 330:178-185, 2005
26. Ogihara T, Asano T, Ando K, Chiba Y, Sekine N, Sakoda H, Anai M, Onishi Y, Fujishiro M, Ono H, Shojima N, Inukai K, Fukushima Y, Kikuchi M, Fujita T: Insulin resistance with enhanced insulin signaling in high-salt diet-fed rats. Diabetes 50: 573-583, 2001
27. Nangaku M, Pippin J, Couser WG: Complement membrane attack complex (C5b-9) mediates interstitial disease in experimental nephrotic syndrome, J Am Soc Nephrol 10: 2323-2331, 1999
28. Schreiber E, Matthias P, Muller MM, Schaffner W: Rapid detection of octamer binding proteins with 'mini-extracts', prepared from a small number of cells. Nucleic Acids Res 17: 6419, 1989
29. Ricardo SD, Bertram JF, Ryan GB: Antioxidants protect podocyte foot processes in puromycin aminonucleoside-treated rats. J Am Soc Nephrol 4: 1974-1986, 1994
30. Wang Y, Rangan GK, Tay YC, Harris DC: Induction of monocyte chemoattractant protein-1 by albumin is mediated by nuclear factor kappaB in proximal tubule cells, J Am Soc Nephrol 10: 1204-1213, 1999
31. Takaya K, Koya D, Isono M, Sugimoto T, Sugaya T, Kashiwagi A, Haneda M: Involvement of ERK pathway in albumin-induced MCP-1 expression in mouse proximal tubular cells. Am J Physiol Renal Physiol 284: F1037-F1045, 2003
32. Mudge SJ, Paizis K, Auwardt RB, Thomas RJ, Power DA: Activation of nuclear factor-kappa B by podocytes in the autologous phase of passive Heymann nephritis. Kidney Int 59: 923-931, 2001
33. Endlich N, Kress KR, Reiser J, Uttenweiler D, Kriz W, Mundel P, Endlich K: Podocytes respond to mechanical stress in vitro. J Am Soc Nephrol 12: 413-422, 2001
34. Pavenstadt H, Kriz W, Kretzler M: Cell biology of the glomerular podocyte. Physiol Rev 83: 253-307, 2003
35. Togawa A, Miyoshi J, Ishizaki H, Tanaka M, Takakura A, Nishioka H, Yoshida H, Doi T, Mizoguchi A, Matsuura N, Niho Y, Nishimune Y, Nishikawa S, Takai Y: Progressive impairment of kidneys and reproductive organs in mice lacking Rho GDIalpha. Oncogene 18: 5373-5380, 1999
36. Yoshimura A, Inui K, Nemoto T, Uda S, Sugenoya Y, Watanabe S, Yokota N, Taira T, Iwasaki S, Ideura T: Simvastatin suppresses glomerular cell proliferation and macrophage infiltration in rats with mesangial proliferative nephritis. J Am Soc Nephrol 9: 2027-2039, 1998
37. Drukker A, Eddy AA: Failure of antioxidant therapy to attenuate interstitial disease in rats with reversible nephrotic syndrome, J Am Soc Nephrol 9: 243-251, 1998
38. Park YS, Guijarro C, Kim Y, Massy ZA, Kasiske BL, Keane WF, O'Donnell MP: Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis 31:190-194, 1998
39. Koop K, Eikmans M, Baelde HJ, Kawachi H, De Heer E, Paul LC, Bruijn JA: Expression of podocyte-associated molecules in acquired human kidney diseases. J Am Soc Nephrol 14: 2063-2071, 2003
40. Smoyer WE, Ransom RF: Hsp27 regulates podocyte cytoskeletal changes in an in vitro model of podocyte process retraction. FASEB J 16: 315-326, 2002
41. Whiteside CI, Cameron R, Munk S, Levy J: Podocytic cytoskeletal disaggregation and basement-membrane detachment in puromycin aminonucleoside nephrosis. Am J Pathol 142: 1641-1653, 1993
42. Mundel P, Shankland SJ: Podocyte biology and response to injury. J Am Soc Nephrol 13: 3005-3015, 2002
43. Takemoto M, Liao JK: Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors. Arterioscler Thromb Vasc Biol 21: 1712-1719, 2001
44. Eddy AA, McCulloch L, Liu E, Adams J: A relationship between proteinuria and acute tubulointerstitial disease in rats with experimental nephrotic syndrome. Am J Pathol 138: 1111-1123, 1991
45. Remuzzi G, Bertani T: Pathophysiology of progressive nephropathies. N Engl J Med 339: 1448-1456, 1998
46. Blanco-Colio LM, Tunon J, Martin-Ventura JL, Egido J: Anti-inflammatory and immunomodulatory effects of statins. Kidney Int 63: 12-23, 2003
47. Sidaway JE, Davidson RG, McTaggart F, Orton TC, Scott RC, Smith GJ, Brunskill NJ: Inhibitors of 3-hydroxy-3-methylglutaryl-CoA reductase reduce receptor-mediated endocytosis in opossum kidney cells. J Am Soc Nephrol 15: 2258-2265, 2004
48. Agarwal R: Statin induced proteinuria: Renal injury or renoprotection? J Am Soc Nephrol 15: 2502-2503, 2004